94 related articles for article (PubMed ID: 20822648)
1. Towards universal ARV access: achievements and challenges in Free State Province, South Africa.
Uebel KE; Timmerman V; Ingle SM; van Rensburg DH; Mollentze WF
S Afr Med J; 2010 Sep; 100(9):589-93. PubMed ID: 20822648
[TBL] [Abstract][Full Text] [Related]
2. Natural control of HIV infection in young women in South Africa: HPTN 068.
Sivay MV; Fogel JM; Wang J; Zhang Y; Piwowar-Manning E; Clarke W; Breaud A; Blankson J; Hamilton EL; Kahn K; Selin A; Gomez-Olive FX; MacPhail C; Hughes JP; Pettifor A; Eshleman SH
HIV Clin Trials; 2018 Oct; 19(5):202-208. PubMed ID: 30522410
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with patients defaulting on HIV treatment at Helen Joseph Hospital, Gauteng province, South Africa.
Potsane P
Afr J AIDS Res; 2023 Jul; 22(2):85-91. PubMed ID: 37337813
[No Abstract] [Full Text] [Related]
4. Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study.
Williams BG; Gupta S; Wollmers M; Granich R
Lancet Public Health; 2017 May; 2(5):e223-e230. PubMed ID: 29253488
[TBL] [Abstract][Full Text] [Related]
5. Designing equitable antiretroviral allocation strategies in resource-constrained countries.
Wilson DP; Blower SM
PLoS Med; 2005 Feb; 2(2):e50. PubMed ID: 15737005
[TBL] [Abstract][Full Text] [Related]
6. The social construction of ARVs in South Africa.
Sember R
Glob Public Health; 2008; 3 Suppl 2():58-75. PubMed ID: 19288353
[TBL] [Abstract][Full Text] [Related]
7. Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion.
Bachmann MO; Timmerman V; Fairall LR
AIDS; 2015 Nov; 29(17):2261-8. PubMed ID: 26544699
[TBL] [Abstract][Full Text] [Related]
8. User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resource country.
Kouanda S; Bocoum FY; Doulougou B; Bila B; Yameogo M; Sanou MJ; Sawadogo M; Sondo B; Msellati P; Desclaux A
AIDS Care; 2010 Sep; 22(9):1146-52. PubMed ID: 20824567
[TBL] [Abstract][Full Text] [Related]
9. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.
Grimsrud A; Cornell M; Schomaker M; Fox MP; Orrell C; Prozesky H; Stinson K; Tanser F; Egger M; Myer L;
J Epidemiol Community Health; 2016 Jun; 70(6):549-55. PubMed ID: 26700300
[TBL] [Abstract][Full Text] [Related]
10. Financing equitable access to antiretroviral treatment in South Africa.
Cleary S; McIntyre D
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S2. PubMed ID: 20594368
[TBL] [Abstract][Full Text] [Related]
11. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi.
Gitura B; Joshi MD; Lule GN; Anzala O
East Afr Med J; 2007 Oct; 84(10):466-72. PubMed ID: 18232267
[TBL] [Abstract][Full Text] [Related]
12. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy.
Maskew M; MacPhail P; Menezes C; Rubel D
S Afr Med J; 2007 Sep; 97(9):853-7. PubMed ID: 17985056
[TBL] [Abstract][Full Text] [Related]
13. Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda.
Bergmann JN; Wanyenze RK; Makumbi F; Naigino R; Kiene SM; Stockman JK
AIDS Behav; 2017 Sep; 21(9):2693-2702. PubMed ID: 27553030
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043).
Fogel JM; Clarke W; Kulich M; Piwowar-Manning E; Breaud A; Olson MT; Marzinke MA; Laeyendecker O; Fiamma A; Donnell D; Mbwambo JK; Richter L; Gray G; Sweat M; Coates TJ; Eshleman SH; Chingono AH
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):158-165. PubMed ID: 27828875
[TBL] [Abstract][Full Text] [Related]
15. Setting ART initiation targets in response to changing guidelines: The importance of addressing both steady-state and backlog.
Martin C; Naidoo NP; Venter WD; Jaffer A; Barker PM
S Afr Med J; 2014 May; 104(6):428-30. PubMed ID: 25214253
[TBL] [Abstract][Full Text] [Related]
16. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
[TBL] [Abstract][Full Text] [Related]
17. [1986-2006: 20 years of failed international policy to control AIDS in Africa].
Kerouedan D
Med Trop (Mars); 2007 Oct; 67(5):515-28. PubMed ID: 18225738
[TBL] [Abstract][Full Text] [Related]
18. Scaling up access to antiretroviral drugs in a middle-income country: public sector drug delivery in the Free State, South Africa.
Steyn F; Schneider H; Engelbrecht MC; van Rensburg-Bonthuyzen EJ; Jacobs N; van Rensburg DH
AIDS Care; 2009 Jan; 21(1):1-6. PubMed ID: 19085214
[TBL] [Abstract][Full Text] [Related]
19. A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.
Huerga H; Shiferie F; Grebe E; Giuliani R; Farhat JB; Van-Cutsem G; Cohen K
BMC Infect Dis; 2017 Sep; 17(1):653. PubMed ID: 28969607
[TBL] [Abstract][Full Text] [Related]
20. Access to antiretroviral therapy among HIV/AIDS patients in Khon Kaen Province, Thailand.
Kitajima T; Kobayashi Y; Chaipah W; Sato H; Toyokawa S; Chadbunchachai W; Thuennadee R
AIDS Care; 2005 Apr; 17(3):359-66. PubMed ID: 15832884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
